89bio Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
89bio (Nasdaq: ETNB) announced the approval of inducement grants by its Board's Compensation Committee. The grants consist of non-qualified stock options to purchase 163,650 shares of common stock, awarded to seven new employees on January 31, 2025. The exercise price equals the closing price of 89bio's stock on the grant date. These options will vest over four years, with 25% vesting after one year and the remaining portion vesting in 12 equal quarterly installments, contingent on continued employment. The grants were made under the company's 2023 Inducement Plan and align with Nasdaq Listing Rule 5635(c)(4).
89bio (Nasdaq: ETNB) ha annunciato l'approvazione di concessioni per inducement da parte del Comitato per la Compensazione del suo Consiglio. Le concessioni consistono in opzioni su azioni non qualificate per l'acquisto di 163.650 azioni ordinarie, assegnate a sette nuovi dipendenti il 31 gennaio 2025. Il prezzo di esercizio è pari al prezzo di chiusura delle azioni di 89bio nella data della concessione. Queste opzioni si matureranno nel corso di quattro anni, con il 25% che matura dopo un anno e la parte restante che matura in 12 rate trimestrali uguali, soggette a continuazione del rapporto di lavoro. Le concessioni sono state effettuate nell'ambito del Piano di Inducement 2023 dell'azienda e sono in linea con la Regola di Quotazione Nasdaq 5635(c)(4).
89bio (Nasdaq: ETNB) anunció la aprobación de concesiones por inducement por parte del Comité de Compensación de su Junta. Las concesiones consisten en opciones de acciones no calificadas para comprar 163,650 acciones ordinarias, otorgadas a siete nuevos empleados el 31 de enero de 2025. El precio de ejercicio es igual al precio de cierre de las acciones de 89bio en la fecha de concesión. Estas opciones se consolidarán durante cuatro años, con el 25% consolidándose después de un año y la parte restante consolidándose en 12 pagos trimestrales iguales, condicionados a la continuación del empleo. Las concesiones se realizaron bajo el Plan de Inducement 2023 de la compañía y están alineadas con la Regla de Cotización de Nasdaq 5635(c)(4).
89bio (Nasdaq: ETNB)는 이사회 보상위원회에서 유인 제안의 승인을 발표했습니다. 이 제안은 163,650주의 보통주를 구매할 수 있는 비자격 주식 옵션으로 구성되어 있으며, 2025년 1월 31일에 7명의 신규 직원에게 부여됩니다. 행사가격은 부여일 기준 89bio의 주식 종가와 같습니다. 이 옵션은 4년 동안 분할 지급되며, 25%는 1년 후에 확정되고 나머지 부분은 지속적인 고용 조건에 따라 12개의 동일한 분기별 할부로 확정됩니다. 이 제안은 회사의 2023 유인 계획에 따라 이루어졌으며 나스닥 상장 규칙 5635(c)(4)에 부합합니다.
89bio (Nasdaq: ETNB) a annoncé l'approbation de subventions d'encouragement par le Comité de Rémunération de son Conseil. Les subventions consistent en des options d'achat d'actions non qualifiées pour acquérir 163 650 actions ordinaires, attribuées à sept nouveaux employés le 31 janvier 2025. Le prix d'exercice est égal au prix de clôture des actions de 89bio à la date de la subvention. Ces options seront acquises sur une période de quatre ans, avec un 25% acquérant après un an et le reste étant acquis en 12 versements trimestriels égaux, sous réserve de la poursuite de l'emploi. Les subventions ont été faites dans le cadre du Plan d'Incitation 2023 de la société et sont conformes à la Règle de Cotation Nasdaq 5635(c)(4).
89bio (Nasdaq: ETNB) hat die Genehmigung von Anreizzuschüssen durch den Vergütungsausschuss seines Vorstands bekannt gegeben. Die Zuschüsse bestehen aus nicht qualifizierten Aktienoptionen zum Kauf von 163.650 Aktien des Stammkapitals, die am 31. Januar 2025 an sieben neue Mitarbeiter vergeben werden. Der Ausübungspreis entspricht dem Schlusskurs der 89bio-Aktien am Tag der Gewährung. Diese Optionen werden über vier Jahre fällig, wobei 25% nach einem Jahr fällig wird und der verbleibende Teil in 12 gleichen vierteljährlichen Raten, abhängig von der fortgesetzten Beschäftigung. Die Zuschüsse wurden im Rahmen des Anreizplans 2023 des Unternehmens gewährt und entsprechen der Nasdaq-Listing-Regel 5635(c)(4).
- Stock-based compensation aligns new employee interests with shareholders
- Structured vesting schedule promotes employee retention
- Potential shareholder dilution from 163,650 new shares
SAN FRANCISCO, Feb. 06, 2025 (GLOBE NEWSWIRE) -- 89bio, Inc. (the “Company” or “89bio”) (Nasdaq: ETNB), a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of liver and cardiometabolic diseases, today announced that the Compensation Committee of the Company’s Board of Directors approved the grant of non-qualified stock options to purchase an aggregate of 163,650 shares of the Company’s common stock to seven new employees (the “Inducement Grants”) on January 31, 2025 (the “Grant Date”). The Inducement Grants have been granted pursuant to the Company’s 2023 Inducement Plan (the “Plan”). The Inducement Grants were granted as an inducement material to these individuals entering into employment with 89bio in accordance with Nasdaq Listing Rule 5635(c)(4).
The Inducement Grants have an exercise price per share that is equal to the closing price of 89bio’s common stock on the Grant Date. The Inducement Grants will vest over a four-year period, with
About 89bio
89bio is a clinical-stage biopharmaceutical company dedicated to the development of best-in-class therapies for patients with liver and cardiometabolic diseases who lack optimal treatment options. The company is focused on rapidly advancing its lead candidate, pegozafermin, through Phase 3 clinical development for the treatment of metabolic dysfunction-associated steatohepatitis (MASH) and severe hypertriglyceridemia (SHTG). Pegozafermin is a specifically engineered, potentially best-in-class fibroblast growth factor 21 (FGF21) analog with unique glycoPEGylated technology that optimizes biological activity through an extended half-life. The company is headquartered in San Francisco. For more information, visit www.89bio.com or follow the company on LinkedIn.
Investor Contact:
Annie Chang
89bio, Inc.
investors@89bio.com
PJ Kelleher
LifeSci Advisors, LLC
+1-617-430-7579
pkelleher@lifesciadvisors.com
Media Contact:
Sheryl Seapy
Real Chemistry
sseapy@realchemistry.com
FAQ
How many shares are included in 89bio's (ETNB) January 2025 inducement grants?
What is the vesting schedule for ETNB's January 2025 inducement grants?
How many new employees received ETNB stock options in January 2025?
What is the exercise price for ETNB's January 2025 inducement grants?
